Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus FLUTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus FLUTEX.
CAPEX vs FLUTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Flutamide is a nonsteroidal antiandrogen that competitively inhibits the binding of dihydrotestosterone (DHT) to androgen receptors in target tissues, thereby blocking the androgenic effects.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
50 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Terminal elimination half-life: 24–36 hours, permitting once-daily dosing in chronic therapy
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Renal: ~70% (50% unchanged, 20% as metabolites); Biliary/fecal: ~30%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid